Coagulation fibrin formation

Mechanism of action - Argatroban is a synthetic, direct thrombin inhibitor that reversibly binds to the thrombin active site. It inhibits thrombin-catalyzed or induced reactions, including fibrin formation activation of coagulation factors V, VIII, and XIII protein C and platelet aggregation. 

Fig.7 Blood compatibility of PEU surfaces modified by MPEO-derived SMAs. A Simplified cascade model for material-induced blood coagulation highlighting three clotting pathways plasma fibrin formation, platelet aggregation, and hemolysis-inflammation, respectively characterized by B-C...

The coagulation process has been reviewed.7 The main approaches to its control are 1. Control of fibrin formation. 2. Control of fibrin-... 

Therapy for the control or prevention of the acute events in death due to vascular disease can be approached in several ways. One general approach would be to control the interaction of blood components with the diseased blood vessel or with each other. In both these cases antithrombotic agents of diverse mechanism should be helpful. Whether control of fibrin formation, fibrinolysis or platelet function is desirable, each patient s problem would dictate the therapy best suited. Several reviews are available in which the different blood coagulation mechanisms that may be helpful in such therapy are discussed s " Reviews have also been published in which methodology is discussed for the testing of compounds and for the determination of abnormalities in platelet function. ... 

Die begins with the activation and production of the proinflam-matory cytokines such as TNF, IL-1, and IL-6, which appear to be the principal mediators, along with endotoxin, of endothelial injury, activation of the coagulation cascade, and inhibition of fibrinolysis. The combination of excessive fibrin formation, inhibited fibrin removal from a depressed fibrinolytic system, and endothelial injury results in microvascular thrombosis and DIC. ... 

---